| 000 | 03596nam a22003857a 4500 | ||
|---|---|---|---|
| 008 | 240807s20242024 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a2234-943X | ||
| 024 | _aPMC11043501 [pmc] | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a38665954 | ||
| 245 | _aImpact of neoadjuvant relugolix on patient-reported sexual function and bother. | ||
| 251 | _aFrontiers in Oncology. 14:1377103, 2024. | ||
| 252 | _aFront. oncol.. 14:1377103, 2024. | ||
| 253 | _aFrontiers in oncology | ||
| 260 | _c2024 | ||
| 260 | _fFY2024 | ||
| 260 | _p2024 | ||
| 265 | _sepublish | ||
| 265 | _tPubMed-not-MEDLINE | ||
| 266 | _d2024-08-07 | ||
| 266 | _z2024/04/26 03:58 | ||
| 520 | _aDiscussion: In concordance with known side effects of androgen deprivation therapy (ADT), neoadjuvant relugolix was associated with a significant decline in self-reported sexual function. However, patients indicated only a minimal and non-significant increase in bother. Future investigations should compare outcomes while on relugolix directly to GnRH agonist-induced sexual dysfunction. Copyright © 2024 Hsueh, Gallagher, Koh, Eden, Shah, Wells, Danner, Zwart, Ayoob, Kumar, Leger, Dawson, Suy, Rubin and Collins. | ||
| 520 | _aIntroduction: Sexual function following local treatment for prostate cancer is an important quality of life concern. Relugolix is a novel oral GnRH receptor antagonist used in combination with radiation therapy in the treatment of unfavorable prostate cancer. It has been shown to achieve rapid and profound testosterone suppression. As a result, these very low testosterone levels may impact both sexual functioning and perceptions. This prospective study sought to assess neoadjuvant relugolix-induced sexual dysfunction prior to stereotactic body radiation therapy (SBRT). | ||
| 520 | _aMethods: Between March 2021 and September 2023, 87 patients with localized prostate cancer were treated with neoadjuvant relugolix followed by SBRT per an institutional protocol. Sexual function and bother were assessed via the sexual domain of the validated Expanded Prostate Index Composite (EPIC-26) survey. Responses were collected for each patient at pre-treatment baseline and after several months of relugolix. A Utilization of Sexual Medications/Devices questionnaire was administered at the same time points to assess erectile aid usage. | ||
| 520 | _aResults: The median age was 72 years and 43% of patients were non-white. The median baseline Sexual Health Inventory for Men (SHIM) score was 13 and 41.7% of patients utilized sexual aids prior to relugolix. Patients initiated relugolix at a median of 4.5 months (2-14 months) prior to SBRT. 95% and 87% of patients achieved effective castration (<= 50 ng/dL) and profound castration (< 20 ng/dl) at SBRT initiation, respectively. Ability to have an erection, ability to reach orgasm, quality of erections, frequency of erections, and overall sexual function significantly declined following relugolix. There was a non- significant increase in sexual bother. | ||
| 546 | _aEnglish | ||
| 650 | _zAutomated | ||
| 656 | _aMedStar Georgetown University Hospital/MedStar Washington Hospital Center | ||
| 656 | _aRadiation Oncology Residency | ||
| 657 | _aJournal Article | ||
| 700 |
_aWells, Markus _bMGUH _cRadiation Oncology Residency _dMD |
||
| 790 | _aHsueh JY, Gallagher L, Koh MJ, Eden S, Shah S, Wells M, Danner M, Zwart A, Ayoob M, Kumar D, Leger P, Dawson NA, Suy S, Rubin R, Collins SP | ||
| 856 |
_uhttps://dx.doi.org/10.3389/fonc.2024.1377103 _zhttps://dx.doi.org/10.3389/fonc.2024.1377103 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c14519 _d14519 |
||